Disease

Melanoma (skin Cancer)

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · PHASE 1/2 TRIAL

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 1b/2 study with no results reported; it documents the protocol and design only.

PreliminaryAMXT 1501 Dicaprate NCT07287917 DFMO

Reported

Planned enrollment92

Study phasesPhase 1b, Phase 2

Primary outcome (Phase 1b)Incidence of Dose-Limiting Toxicities (DLTs…

AUG 11, 2026 · PHASE 1/2 TRIAL

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

ClinicalTrials.gov

This is a Phase 1/2 trial registration with no reported results; the study is actively recruiting and has not yet established safety, tolerability, or efficacy of the combination.

PreliminaryBexmarilimab 1mg/kg and nivolumab 1mg/kg Institute of Cancer Research, United Kingdom Melanoma (skin Cancer)

Reported

Estimated enrollment62

PhasePhase 1/Phase 2

Primary endpoint (Phase 1)Recommended Phase II dose of bexmarilimab i…